Affinia secures $1.6bn worth deal from Vertex to develop AAV capsids for genetic therapies

Affinia Therapeutics has signed a research collaboration deal worth more than $1.6bn with Vertex Pharmaceuticals to discover and develop adeno-associated virus capsids (AAV capsids) to be used in the latter's genetic therapies aimed at treating people with serious diseases.